Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs: Cytotoxicity, DNA binding, cellular uptake, and metabolism

Biochemical Pharmacology

Volumn 60, Issue 7, 2000, Pages 969-978

  Siim, Bronwyn G ^a,b   Hicks, Kevin O ^b   Pullen, Susan M ^b   Van Zijl, Pierre L ^a   Denny, William A ^b   Wilson, William R ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bioreductive drug metabolism; Cellular uptake; DNA binding; Log P; N oxides; Nitroacridines

Indexed keywords

ACRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATIC AMINE; INTERCALATING AGENT; TERTIARY AMINE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHO CELL; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; DRUG DETERMINATION; DRUG DNA BINDING; DRUG EFFECT; DRUG METABOLISM; DRUG SCREENING; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL TRANSPORT; CELL SURVIVAL; CELLS, CULTURED; CHO CELLS; CRICETINAE; DNA; INTERCALATING AGENTS; NITRACRINE;

EID: 0034308202     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00420-2     Document Type: Article

References (38)

1. Stone H.B., Brown J.M., Phillips T.L., Sutherland R.M. Oxygen in human tumors Correlations between methods of measurement and response to therapy . Radiat Res. 136:1993;422-434.
2. Raleigh J.A., Dewhirst M.W., Thrall D.E. Measuring tumor hypoxia. Semin Radiat Oncol. 6:1996;37-45.
3. Gatenby R.A., Kessler H.B., Rosenblum J.S., Coia L.R., Moldofsky P.J., Hartz W.H. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 14:1988;831-838.
4. Nordsmark M., Overgaard M., Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 41:1996;31-39.
5. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379:1996;88-91.
6. Cuvier C., Jang A., Hill R.P. Exposure to hypoxia, glucose starvation and acidosis Effect on invasive capacity of murine tumor cells and correlation with cathepsin (L+B) secretion . Clin Exp Metast. 15:1997;19-25.
7. Brown J.M., Siim B.G. Hypoxia specific cytotoxins in cancer therapy. Semin Radiat Oncol. 6:1996;22-36.
8. Denny W.A., Wilson W.R., Hay M.P. Recent developments in the design of bioreductive drugs. Br J Cancer. 74:(Suppl 27):1996;S32-S38.
9. Stratford I.J., Workman P. Bioreductive drugs into the next millenium. Anti-Cancer Drug Des. 13:1998;519-528.
10. Kwasniewski-Rokicinska C., Swiecki J., Wieczorkiewicz A. Therapeutic efficacy of compound C-283 in patients with mammary carcinoma. Archiv Immunol Ther Exp. 21:1973;863-869.
11. Wilson W.R., Denny W.A., Twigden S.J., Baguley B.C., Probert J.C. Selective toxicity of nitracrine to hypoxic mammalian cells. Br J Cancer. 49:1984;215-223.
12. Wilson W.R., Denny W.A., Stewart G.M., Fenn A., Probert J.C. Reductive metabolism and hypoxia-selective toxicity of nitracrine. Int J Radiat Oncol Biol Phys. 12:1986;1235-1238.
13. Lee H.H., Wilson W.R., Ferry D.M., van Zijl P., Pullen S.M., Denny W.A. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide. J Med Chem. 39:1996;2508-2517.
14. Wilson W.R., van Zijl P., Denny W.A. Bis-bioreductive agents as hypoxia-selective cytotoxins Nitracrine N-oxide . Int J Radiat Oncol Biol Phys. 22:1992;693-696.
15. Siim B.G., Denny W.A., Wilson W.R. Does DNA targeting affect the cytotoxicity and cell uptake of basic nitroquinoline bioreductive drugs? Int J Radiat Oncol Biol Phys. 29:1994;311-315.
16. Siim B.G., Atwell G.J., Anderson R.F., Wardman P., Pullen S.M., Wilson W.R., Denny W.A. Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-alkylamino-5-nitroquinoline bioreductive drugs. J Med Chem. 40:1997;1381-1390.
17. Burger A.M., Jenkins T.C., Double J.A., Bibby M.C. Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridine antineoplastic agent C1311. Br J Cancer. 8:1999;367-375.
18. Hicks K.O., Ohms S.J., van Zijl P.L., Denny W.A., Hunter P.J., Wilson W.R. An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br J Cancer. 76:1997;894-903.
19. Tunggal J.K., Cowan D.S.M., Shaikh H., Tannock I.F. Penetration of anticancer drugs through solid tissue A factor that limits the effectiveness of chemotherapy for solid tumors . Clin Cancer Res. 5:1999;1583-1586.
20. Patterson L.H. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents A new class of bioreductive agent . Cancer Metast Rev. 12:1993;119-134.
21. Patterson L.H., Craven M.R., Fisher G.R., Teesdale-Spittle P. Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs. Oncol Res. 6:1995;533-538.
22. Wilson W.R., Denny W.A., Pullen S.M., Thompson K.M., Li A.E., Patterson L.H., Lee H.H. Tertiary amine N-oxides as bioreductive drugs DACA N-oxide, nitracrine N-oxide and AQ4N . Br J Cancer. 74:(Suppl. 27):1996;S43-S47.
23. Wang J., Beidermann K.A., Brown J.M. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res. 52:1992;4473-4477.
24. Monge A., Palop J.A., de Ceráin A.L., Senador V., Martinez-Crespo F.J., Sainz Y., Narro S., Garcia E., De Miguel C., González M., Hamilton E., Barker A.J., Clarke E.D., Greenhow D.T. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides. J Med Chem. 38:1995;1786-1792.
25. Naylor M.A., Adams G.E., Haigh A., Cole S., Jenner T., Robertson N., Siemann D., Stephens M.A., Stratford I.J. Fused pyrazine mono-N-oxides as bioreductive drugs III. Characterization of RB 90740 in vitro and in vivo. Anticancer Drugs. 6:1995;259-269.
26. von Pawel J and von Roemeling R, Survival benefit from tirazone (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: Final results from the international phase III CATAPULT 1 trial. Proc Am Soc Clin Oncol 17: 454a (Abstract # 1749), 1998.
27. Stefanska B., Ledochowski A. Research on tumour inhibiting compounds. Part XLV. Derivatives of 1- and 3-nitroaminoacridine N-oxides. Roczniki Chemii. 42:1968;1973-1980.
28. Siim B.G., Atwell G.J., Wilson W.R. Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs. Br J Cancer. 70:1994;596-603.
29. Siim B.G., Atwell G.J., Wilson W.R. Metabolic and radiolytic reduction of 4-alkylamino-5-nitroquinoline bioreductive drugs Relationship to hypoxia-selective cytotoxicity . Biochem Pharmacol. 48:1994;1593-1604.
30. Denny W.A., Chambers D., Stewart G.M., Wilson W.R. Nitroacridines with selective toxicity towards hypoxic mammalian cells Synthesis and stability of tritiated derivatives . J Labelled Comp Radiopharm. 21:1985;995-1005.
31. Rivory L.P., Avent K.M., Pond S.M. Effects of lipophilicity and protein binding on the hepatocellular uptake and hepatic disposition of two anthracyclines, doxorubicin and iododoxorubicin. Cancer Chemother Pharmacol. 38:1996;439-445.
32. Shah J.C., Chen J.R., Chow D. Preformulation study of etoposide Identification of physicochemical characteristics responsible for the low and erratic bioavailability of etoposide . Pharm Res. 6:1989;408-412.
33. Krogstad D.J., Schlesinger P.H. A perspective on antimalarial action Effects of weak bases on Plasmodium falciparum . Biochem Pharmacol. 35:1986;547-552.
34. McGhee J.D., von Hippel P.H. Theoretical aspects of DNA-protein interactions Cooperative and noncooperative binding of large ligands to a one-dimensional homogeneous lattice . J Mol Biol. 86:1974;469-489.
35. Record M.T., Lohman T.M., de Haseth P. Ion effects on ligand-nucleic acid interactions. J Mol Biol. 107:1976;145-158.
36. Perrin D.D. Dissociation Constants of Organic Bases in Aqueous Solution. 1965;Butterworths, London.
37. Boyd M., Denny W.A. NMR studies of configuration and tautomeric equilibria in nitroacridine antitumor agents. J Med Chem. 33:1990;2656-2659.
38. Sutton BM, Nitracrine-an Experimental Hypoxia Selective Cytotoxin, PhD Thesis, The University of Auckland, 1989.